Trials / Completed
CompletedNCT04465955
A Study of NGM621 in Participants With Geographic Atrophy
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM621 | NGM621 Dose 1 |
| BIOLOGICAL | NGM621 | NGM621 Dose 2 |
| OTHER | Sham Comparator | Sham Comparator |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2022-08-16
- Completion
- 2022-08-16
- First posted
- 2020-07-10
- Last updated
- 2025-07-01
- Results posted
- 2025-07-01
Locations
65 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04465955. Inclusion in this directory is not an endorsement.